Training in Pharmacometrics and the Therapeutic Application of Nanotechnology

药理学和纳米技术治疗应用培训

• 批准号: 7173490
• 负责人: David G. Poplack
• 金额: $ 12.75万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-10 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7173490
• 关键词: Training; Pharmacometrics; Therapeutic; Application; Nanotechnology

DESCRIPTION (provided by applicant): The primary aim of this application for the Mentored Specialized Clinical Investigator Development Award (MSCIDA) in Pediatric Pharmacology is to provide a comprehensive training program in pediatric clinical pharmacology for Dr. Patrick A. Thompson, a board-eligible pediatrician and sub-specialty fellow in hematology-oncology. Patrick has a unique background in engineering, mathematical modeling and clinical medicine. This comprehensive training program for Dr. Thompson has been tailored to 1) further develop his capabilities in pharmacokinetic modeling and pharmacokinetic, pharmacodynamic and pharmacogenetic correlations, 2) provide him with the knowledge and ability to design, conduct, and analyze pediatric clinical therapeutics trials, 3) give him a thorough understanding of the complex regulatory issues associated with pediatric labeling of drugs and biology, and 4) teach him to carry out translational research in pharmacology. His training will occur through Baylor College of Medicine's( BCM) Pediatric Pharmacology Research Unit (PRRU) and will include formal enrollment in the BCM Clinical Pharmacology Fellowship Program, which is registered with the American Board of Clinical Pharmacology. The BCM Clinical Pharmacology fellowship program curriculum covers all the topics required by the MSCIDA award. It includes participation in BCM's, NIH-K30 grant-supported Clinical Scientist Training Program (CSTP), formal coursework at the University of Houston College of Pharmacy, and clinical rotations through the University of Texas and Texas Children's Hospital. The didactic component of this fellowship also includes outside rotations at the Food and Drug Administration, with the pharmaceutical industry, and with experts in population-based modeling at a collaborating PPRU site. The research component of Dr. Thompson's career plan includes two projects: 1) a pharmacometric project to evaluate the pharmacokinetic variability of an important anticancer agent, irinotecan, utilizing population modeling techniques; and 2) a project to characterize the pharmacology and biodistribution of two types of therapeutic antibody-targeted gold nanoparticles that have promising applications for the treatment of malignant or other disease processes. The proposed Career Development Plan for Dr. Thompson will provide an excellent foundation for achieving his long-term goal of becoming a leading clinician-scientist and educator in pediatric clinical pharmacology.

描述（由申请人提供）：本申请儿科药理学指导专业临床研究者发展奖（MSCIDA）的主要目的是为Patrick a . Thompson博士提供儿科临床药理学的综合培训计划，Patrick a . Thompson博士是一名符合委员会资格的儿科医生和血液肿瘤学亚专科研究员。帕特里克在工程、数学建模和临床医学方面有着独特的背景。这项针对Thompson博士的综合培训计划旨在：1)进一步发展他在药代动力学建模、药代动力学、药效学和药物遗传学相关性方面的能力；2)为他提供设计、实施和分析儿科临床治疗试验的知识和能力；3)让他全面了解与儿科药物标签和生物学相关的复杂监管问题。4)指导他开展药理学的转化研究。他的培训将通过贝勒医学院（BCM）儿科药理学研究部门（PRRU）进行，并将包括在美国临床药理学委员会注册的BCM临床药理学奖学金计划的正式注册。BCM临床药理学奖学金项目课程涵盖了MSCIDA奖所需的所有主题。它包括参加BCM， NIH-K30资助的临床科学家培训计划（CSTP），在休斯顿大学药学院的正式课程，以及在德克萨斯大学和德克萨斯儿童医院的临床轮转。该奖学金的教学内容还包括在食品和药物管理局（fda）与制药行业的外部轮岗，以及与PPRU合作站点的人口建模专家的轮岗。Thompson博士职业规划的研究部分包括两个项目：1)药物计量学项目，利用人口建模技术评估重要抗癌药物伊立替康的药代动力学变异性；2)表征两种治疗性抗体靶向金纳米颗粒的药理学和生物分布的项目，这些纳米颗粒在治疗恶性或其他疾病过程中具有很好的应用前景。汤普森博士提出的职业发展计划将为实现他成为儿科临床药理学领域领先的临床科学家和教育家的长期目标提供良好的基础。